OMC
NTLA icon

Old Mission Capital’s Intellia Therapeutics NTLA Stock Holding History

Old Mission Capital’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-14,935
Closed -$258K – 1198
2025
Q3 		$258K Buy
+14,935
New +$184K 0.01% 923

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Old Mission Capital's NTLA Position: Q4 2025 in Review

Old Mission Capital sold out of Intellia Therapeutics (NTLA) in Q4 2025, closing a stake of 14,935 shares — an estimated $258K sold.

Old Mission Capital first reported a position in NTLA in Q3 2025 and held it in 1 quarter. The position peaked at $258K in Q3 2025. 291 funds tracked by Wall St. Rank hold NTLA as of Q4 2025.

  • Old Mission Capital reported no remaining Intellia Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Old Mission Capital sold 14,935 Intellia Therapeutics shares in Q4 2025, an estimated $258K.
  • Old Mission Capital first reported a position in Intellia Therapeutics in Q3 2025 and held it in 1 quarter.
  • Old Mission Capital's Intellia Therapeutics position peaked at $258K in Q3 2025.
  • 291 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q4 2025.

Based on Old Mission Capital's 13F filing for Q4 2025, filed 17 Feb 2026.